BioSpace News Archive

Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2022, which reflect robust in-line product growth, increased adoption of new product portfolio and strong commercial execution.

Abeona Therapeutics Inc. today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 1,000,006 shares of Series A convertible redeemable preferred stock and 250,005 shares of Series B convertible redeemable preferred stock.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after the close of the United States financial markets on Thursday, May 5th, 2022.

Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter ended March 31, 2022.

Abbott (NYSE: ABT) today announced results from the PERSIST-END study, which showed that nearly nine out of 10 patients (89%) treated for persistent atrial fibrillation (AFib) with the company’s TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) remained symptom-free for up to 15 months following the procedure.

Athersys, Inc. (Nasdaq: ATHX) today announced that it will release its first quarter 2022 financial results on Friday, May 6, 2022, at 8:00 a.m. EDT.

Avinger, Inc., announced that it will release its financial results for the first quarter 2022 after the close of trading on Tuesday, May 10, 2022.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), announces today that it has appointed Shishir Sinha, the Company’s newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company’s diagnostics division.

Representatives of Rafarma Pharmaceuticals, Inc. visited Uzbekistan and discussed the prospects for the company’s development in the territory of the innovative research and production pharmaceutical cluster “Tashkent Pharma Park”.

Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights.